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OX26 variants with affinities of 76 nM and 108 nM showed enhanced brain and CSF exposure and higher potency in Hargreaves model, compared to a 5 nM affinity variant; lowering affinity to 174 nM resulted in prolonged serum pharmacokinetics, but reduced brain and CSF exposure.
The study demonstrates that binding affinity optimization of TfR>binding antibodies could improve their brain and CSF exposure even in the absence of mono>valent TfR engagement.
: blood>brain barrier; transferrin receptor antibody; affinity optimization; pharmacokinetics; brain exposure; inflammatory pain 3 Antibodies have emerged as a class of therapeutics that can be engineered to demonstrate an exquisite selectivity, specificity and affinity, or to engage multiple targets, and therefore have significant advantages over synthetic molecules for some therapeutic indications. 1 The blood brain barrier (BBB), formed by the tight>junction sealed brain endothelial cells, presents a major impediment for developing efficacious antibody>based therapeutics for central nervous system (CNS) diseases. 2, 3 However, the delivery of CNS>targeting antibodies across the BBB can be achieved by 'coupling' them with carrier molecules that engage the BBB receptor>mediated transcytosis (RMT) process. 2, 4, 5 The most studied receptor undergoing RMT is transferrin receptor (TfR). This receptor is enriched in brain endothelial cells compared to peripheral endothelium, 6, 7 but it is also abundant in blood cells (bone marrow; reticulocytes) and lung. 8 The trafficking of transferrin and anti>transferrin receptor antibodies across the BBB by RMT has been demonstrated in vitro and in vivo.
9,10
The attributes of anti>TfR antibodies studied in relation to their ability to efficiently transcytose across the BBB include affinity, 11 valency, 12 and pH sensitivity of receptor binding. 13 Notably, it has been shown that antibodies displaying high>affinity binding to TfR preferentially accumulate in brain vessels without efficient release on the abluminal side of brain endothelium. 11, [14] [15] [16] [17] Lowering their affinity facilitated their sorting into early endosomes, 18 improved their transcytosis and increased their levels in the brain parenchyma. 11, 19 The comparisons of TfR engagement with bi>valent or monovalent TfR antibodies revealed that a monovalent format achieved improved transcytosis across the BBB, regardless of affinity, 12 whereas a high>affinity bi>valent antibody was destined to degradation in brain endothelial lysosomes. 12 A pH>sensitive bi>valent TfR antibody, with lower binding affinity at the acidic pH found in endocytic compartments, also demonstrated improved BBB transcytosis in vitro. 13 4 from 1.2 nM to 130 nM resulted in a 44>fold increase in total brain and spinal cord exposure 19 .
The various studies above examined TfR antibodies that bound different epitopes on TfR and it is therefore difficult to extend their findings into generic principles that govern TfR>anti>TfR -mediated transcytosis across the BBB.
In this study we developed affinity variants of the known rat TfR>specific antibody OX26
and evaluated their pharmacokinetics, brain and CSF exposure to examine whether affinity modulation/optimization of bi>valent anti>TfR antibodies binding the same receptor epitope is sufficient to improve their brain and CSF exposure and to engage central target. The data demonstrate that OX26 with affinities in the 76>108 nM range produced a significantly higher CNS exposure, neuronal cell engagement and higher potency in pharmacodynamics chronic pain model, compared to either high affinity (5 nM) or low affinity (174 nM) variants binding the same epitope.
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DNA encoding the V H and V L of the mouse anti>rat TfR antibody OX26 was synthesized by Life Technologies (Carlsbad, CA) and cloned into expression vectors containing the appropriate light or heavy chain constant regions. 20 Single alanine substitutions were introduced into the V H complementarity determining region 1 (CDR1) and V H or V L CDR3
regions of OX26 by site>directed mutagenesis. Unless otherwise stated, OX26 variants were expressed as chimeric human IgG1 molecules with the S239D/A330L/I332E triple mutation (IgG1 TM) 21 (Supplementary Table 1 ). Antibodies were expressed in transiently transfected
Chinese hamster ovary (CHO) cells in serum>free media as described previously. 22 Cultures were maintained in a humidified incubator at 37°C, 5% CO 2 for 14 days after which the medium 5 was harvested. Antibodies were purified from cell culture media using protein A affinity chromatography followed by size exclusion chromatography. The concentration of IgG was determined by A 280 using an extinction coefficient based on the amino acid sequence of the IgG.
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The control antibody, NiP228, a full IgG binding to the hapten nitrophenol, of identical isotype to the test antibodies, was produced and purified using the same methods. In some experiments, fusion of A20.1, a camelid single>domain antibody against C. difficile toxin B, and the mouse Fc (A20.1mFc), also expressed in CHO cells, was used for normalization of responses across experimental groups.
To allow site>specific conjugation of bio>active drug molecules, antibodies were generated containing three cysteine residues introduced into the solvent exposed surface of the Fc region.
The extracellular domain (L101 to F761) of rTfR was expressed with flag and 10His tags at its C>terminus. Expression was performed in CHO cells as described above and the protein was purified by Ni>affinity and size exclusion chromatography.
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Affinity of OX26 variants for rTfR was determined using an assay in which binding was monitored using the Octet RED384 System (Pall ForteBio LLC, Menlo Park, CA). Human IgG1 TM molecules were immobilized onto anti>human Fc capture biosensors at 10 Mg/mL in Octet kinetics buffer (PBS containing1 mg/mL BSA and 0.01% Tween>20). Association of rTfR was monitored at receptor concentrations of 1>2000 nM for 300 seconds after which dissociation was monitored for 300 seconds. Binding curves were fit with a 1:1 binding model to generate kinetic parameters using Octet Data Analysis Software.
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All studies to measure antibody exposure in the periphery and brain were performed at Quotient Biosciences (Newmarket, UK) in male Sprague>Dawley rats.
CSF collections and Hargreaves model of inflammatory pain were performed at the National Research Council (NRC) of Canada. All animal procedures were approved by the NRC's Animal Care Committee and were in compliance with the Canadian Council of Animal Care guidelines. All animals were purchased from Charles River Laboratories International, Inc.
(Wilmington, MA, USA). Animals were housed in groups of three in a 12>hour light/dark cycle at a temperature of 24°C, a relative humidity of 50 ± 5%, and were allowed free access to food and water. Male Wistar rats aged 8>10 weeks (weight range, 230-250 g) were used in these studies.
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Five groups of male Sprague>Dawley rats were intravenously injected with each of the anti>rTfR antibodies or control IgG at 20 mg/kg. Intravenous doses were administered into a tail vein at a constant dose volume of 10 ml/kg. Antibodies were supplied in D>PBS (Sigma).
Following dosing, three blood plasma samples were collected into individual Li>Heparin containers from each of six animals per time point. Plasma samples were taken at the following times post>dose for all dose groups -10 minutes, 1, 2, 4, 6, 8, 24, 48 and 72 hours.
The first and second blood samples from each animal were collected from the lateral tail vein (ca 400 Ml) into a Li>Hep microtainer (BD Diagnostic Systems), while the final sample (ca 5 ml) was collected by cardiac puncture under isoflurane anaesthesia into a Li>hep container (BD Diagnostic Systems). Following collection, blood samples were centrifuged at 10,000 x g for 2
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minutes at 4°C and the resultant plasma drawn off. Terminal blood samples were centrifuged at 2500 x g for 10 minutes at 4°C. Plasma samples were flash frozen on dry ice for subsequent analysis. After final blood collection each animal remained under anaesthesia and had the chest cavity opened to allow access to the heart. A 50 ml syringe with attached 16G needle pre> loaded with PBS was inserted into the left ventricle. The right ventricle was then carefully cut prior to gentle perfusion until the extremities (paws and ears) appeared white. The animal was considered fully perfused after 50 ml D>PBS had been administered. The cranium of each animal was opened and the brain fully removed and divided into two hemispheres. One hemisphere was snap frozen in liquid nitrogen, and the second hemisphere was weighed and homogenized as detailed below.
Brain hemispheres were individually homogenized in 5 volumes of ice>cold PBS containing 1% NP>40 and Complete® protease inhibitor cocktail tablets (Roche Diagnostics).
Homogenization was achieved in a 10 ml Potter>Elvehjem mortar type glass homogenizer with PTFE pestle, using 2x10 clockwise strokes with 5 sec rest time. Homogenates were transferred to LoBind tubes (Eppendorf) and rotated at 4°C for 1 hour before centrifuging in a chilled bench> top centrifuge at 13,000 g for 20 minutes to remove cell debris, including capillaries. The resulting capillary free supernatant was carefully removed for brain antibody measurement as described. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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In these experiments, a combination of control and 'test' antibodies was administered i.v.
into tail vein in equimolar doses. CSF sample collections were made from cisterna magna by needle puncture up to five times over 96 hours. For sample collection rats were briefly and lightly anesthetized with 3% isoflurane, placed in a stereotaxic frame with the head rotated downward at a 45° angle. A 2> cm midline incision between the ears beginning at the occipital crest was made and muscles separated to expose dura mater covering cisternae magna. A 27G butterfly needle (QiuckMedical, Cat# SV27EL) with tubing attached to 1 ml syringe was used to puncture dura and aspirate the ~20 l of CSF. The CSF is then transferred into the sample glass vial (Waters, Cat#186000384c) and placed in −80°C freezer until further analysis. Blood samples were collected from the tail vein in a commercially available tube (BD microtainer, Cat# 365956). After clotting at room temperature for 15>30 minutes, the clot was removed by centrifuging at 1100 rcf (3422rpm) for 10 minutes; serum is then transferred into a clean glass vial (Waters, Cat#186000384c), frozen on dry ice and then stored at >80°C until further analysis. At the end of collection, rats were sacrificed by cardiac puncture.
CSF and serum levels of antibodies were determined using multiplex SRM analytical method as described in following sections.
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OX26 affinity variants and control antibody levels in blood and CSF samples were quantified using targeted nanoLC MS/MS.
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Filter>aided sample preparation method was used to prepare the samples for mass spectrometry. 25 Briefly, each sample was reduced in 3.5% SDS, 100 mM Tris>HCl, 100 mM DTT by boiling for 10 minutes. A 6.6>volume of Urea solution (8M Urea, 100 mM Tris>HCl, pH 8.5) was added to the sample and they were transferred to pre>wetted Amicon>30 spin columns (Millipore, Billerica, MA, USA) and spun as per manufacturer's instructions. The proteins were washed three times with the Urea solution, alkylated (10 mM iodoacetamide, 30>60 minutes at room temperature in dark), and then washed four times with the Urea solution and four times with 50 mM ammonium bicarbonate. The samples were digested using trypsin at 37°C and the peptides were eluted for SRM analysis. To develop the SRM assay for proteins, samples (pure antibodies and endosome fractions)
were first analyzed by nanoLC>MS/MS using data>dependent acquisition to identify ionizible peptides of antibodies used (Supplementary Table 2 ). Once these spectra were validated as unique signatures, multiplexed methods of these peptides were created for SRM analysis to allowed targeted quantification of the proteins in the fraction. SRM analyses were carried out as previously described. 26 For ILIS>based quantification, isotopically heavy versions of the peptides were synthesized (New England Peptide LLC, Gardner, MA) containing heavy C>terminus K (+8 Da). SRM analyses were carried out as previously described.
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The blood contamination of CSF samples was evaluated by 'in>reaction' monitoring of albumin levels using a nanoLC>SRM method and albumin signatures as described previously 26 .
A CSF/serum ratio of albumin higher than 0.07% was considered blood contamination and these CSF samples were excluded from further analyses. 
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Antibody conjugation to galanin
The neuropeptide galanin, YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY, was chemically synthesised by Bachem (Bubendorf, Switzerland) with a maleimide group attached to the C>terminus via the ε>amino group of an additional lysine residue to allow conjugation to thiol group of engineered cysteine residues on the Fc region of human antibodies. 27 Briefly, to achieve site specific peptide conjugation, cysteine engineered OX26 variant antibodies, were first reduced with 40 molar equivalents of Tris>(2>carboxyethyl)>phosphine (TCEP) in PBS pH7.2, 1mM EDTA (Ethylenediaminetetraacetic acid) for 3 hours at room temperature.
Following buffer exchange to remove TCEP, 20 molar equivalents of dehydroascorbic acid (dhAA) were added for 4 hours at room temperature. The resulting solution was filtered through a 0.2 uM syringe filter and 7.5 molar equivalent of the galanin peptide was then added followed by incubation at room temperature for 1 hour and subsequently at 4°C overnight. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 14 column in PBS. The peptide to antibody ratio was estimated as described in Thompson et al. 27 Briefly, the extent of conjugation was determined by measuring the mass shift between unlabelled and labelled antibody by matrix>associated laser desorption/ionization time>of>flight mass spectrometry performed on a Shimadzu Biotech Axima Assurance mass spectrometer.
Galanin conjugated antibodies had an average drug>antibody ratio (DAR) of 4>5. Endotoxin levels were measured using the Charles River Endosafe>PTS system and all antibodies used for in vivo studies contained <1 EU/mg. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The statistical significance used to compare differences between treatments in behavioral experiments was determined by One>way analysis of variance (ANOVA), followed by Tukey's test. Differences were considered statistically significant at P <0.05.
To generate a panel of OX26 variants with reduced affinity for rTfR, single alanine substitutions were introduced into HCDR1, HCDR3 or LCDR3 and resulting mutants were characterized using an Octet binding assay. An affinity of 5 nM was measured for wild>type OX26 ( Table 1 ). The majority of alanine substitutions had little or no effect on affinity of the antibody. However, a number of variants were identified that had between 5> and 70>fold 
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To evaluate CSF levels of OX26 affinity variants, we used a sensitive mass spectroscopy SRM method applicable for very small sample volumes of CSF obtained by repeated collections over 96 h, described in detail previously. 29, 30 The method allows for simultaneous (multiplexed) measurements of co>injected control antibody, as well as albumin levels in CSF to control for potential blood contamination. An OX26 variant or NiP228 and control antibody A20.1mFc, used for normalization across experiments and to ensure that the BBB is intact in each animal, were co>injected into tail vein at equimolar (30 nmol/kg) doses.
The CSF levels measured for A20.1mFc in all experiments were below 0.7 nM at 6 h and 24 h, and declined to <0.05 nM at subsequent time points (48>96h) (Figure 1B ), giving 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 serum/CSF ratio over time of ~0.1%. Similar CSF levels were measured for control antibody NiP228 ( Figure 1B) , confirming minimal penetration of these two control molecules into CSF.
OX26 5 , OX26 76 and OX26 108 all showed higher CSF exposure compared to either A20.1mFc or NiP>228 ( Figure 1B , Table 3 ), whereas OX26 174 exhibited slightly, but not significantly higher CSF levels compared to control antibodies ( Figure 1B , Table 3 Galanin and its receptors play an important role in the transmission and modulation of nociceptive information in the brain. 31 When administered systemically, this neuropeptide has no analgesic effects since it cannot cross the BBB. 32 However, injecting galanin directly into the brain has been shown to induce analgesia in different models, including the Hargreaves model of chronic inflammatory pain. 31, 33 In Supplementary Figure 2 To enable ranking of potency of different variants, the dosing of variants was initially titrated so that the maximal response falls below 100% for the best>crossing variant. Therefore, the potency among OX26 affinity variants was compared at equimolar 10 nmol/kg dose. was measured as the higher percent reversal, longer duration of the response and AUC of the response (Table 4) . At the end of experiments (240 minutes), serum and CSF samples were harvested from each animal to measure levels of variants ( Figure 3B ). CSF levels of OX26 76 and OX26 108 were higher compared to OX26 5 , whereas CSF levels of OX26 174 were similar to those of NiP228.
Intravenous injection of galanin>conjugated OX26>affinity variants induced a time dependent
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The delivery of therapeutic cargo across the BBB using anti>TfR antibodies to engage 12 provided evidence that the mono>valent engagement of the TfR by the antibody led to its escape from lysosomal degradation and delivery into brain parenchyma.
Neither group had fully controlled (matched) the binding affinity of anti>TfR antibodies in their mono> and bi>valent formats, leaving both explanations equally plausible. Furthermore, anti>TfR antibodies used in these studies bound distinct epitopes on the TfR, another variable that could influence the nature of TfR trafficking and recycling across the BBB. The brain exposure of systemically administered RMT>targeting antibodies depends on multiple parameters, among others the BBB abundance of RMT receptor and its recycling rates, antibody ability to bind/engage and release from RMT receptor, as well as on its peripheral pharmacokinetics and biodistribution. 40 Ideally, the BBB>carrier antibody should bind highly and selectively expressed target on brain vascular cells that is not present or is low abundant in both peripheral organs and in the brain parenchyma, so that the peripheral and brain disposition and elimination of bispecific molecules is determined predominantly by the properties of the therapeutic cargo. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 23 binding affinity at either regular or acidic pH. 11,13 Consistent with these findings were the observations from this study that OX26 variants with lower affinities of 76 nM and 108 nM exhibited higher total brain levels as well as detectable co>localization with neuronal bodies.
Whilst 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 have shown that systemically administered high>affinity antibody against mGluR1, an abundant central target, fused to an alternative BBB carrier, displays higher brain levels in combination with lower CSF exposure compared to the BBB>fused antibody that has no central target,
suggesting that the high fraction of 'bound' antibody reduces 'free' antibody available for the exchange with CSF. 43 In the case of anti>TfR antibodies, the target is highly expressed in both peripheral and central compartments, and their affinity could significantly affect not only systemic pharmacokinetics and BBB delivery, but also their central disposition (unbound fraction) and pharmacology. In this study, we have also assessed CSF levels of OX26 affinity variants. CSF levels reflect the ability of the antibody to cross the blood>cerebrospinal fluid (BCSF) barrier without crossing the BBB, a likely scenario for OX26 5 , or to transverse both BCSF and BBB, where brain interstitial fluid (ISF) exchange with CSF contributes to further increases in CSF levels as observed for lower affinity variants OX26 76 and OX26 108 .
The OX26 affinity variants chemically cross>linked with the anti>nociceptive peptide galanin were evaluated in the pharmacodynamic Hargreaves model of thermal hyperalgesia.
The AUC of pharmacodynamics response showed the same ranking order of OX26 variants as it was observed by measuring their brain exposure: NiP228<OX26 5 =OX26 174 <OX26 108 =OX26 76 .
OX26 76 >Gal was 3>fold more potent than OX26 6 >Gal. Since the inhibition of thermal hyperalgesia in Hargreaves model can be measured over ~4 hours only, due to desensitization of nociceptive receptors, 40 and since the serum pharmacokinetics over this period is similar among variants, the CSF levels at the end of pharmacodynamic experiment were measured as time>matched correlate of the pharmacodynamics response; the CSF levels of variants demonstrated a strong association with the extent of their pharmacological response. In accordance with this study, another recent study 19 demonstrated that lowering the affinity of the mouse>selective anti>TfR antibody 8D3 to a range of 60>130 nM significantly improved its ability to deliver anti>nociceptive 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 IL>1 receptor antagonist (IL>1RA) across the blood>brain> and blood>spinal cord barriers. The pharmacological response lasted up to 7 days in a neuropathic mechanical hypersensitivity pain model in mice. Both this study in mice and our study in rats used a bi>valent, IgG format of the species>specific TfR antibody and showed that lowering their binding affinities to ~100 nM is sufficient to improve their total brain exposure in the absence of mono>valent binding to the receptor. The notable difference between OX26 and 8D3 affinity variants used in these two studies is that OX26 affinity modulation was achieved primarily by faster dissociation rates, whereas reductions in 8D3 affinities were driven by slower association rates. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 26 in the development of clinically viable brain>targeting bi>specific molecules using TfR antibodies as BBB>crossing carriers. A further interesting observation from PK>PD modeling studies with TfR>BACE1 bi>specific antibodies 42, 43 is that the 'benefit' of TfR variants in improving antibody brain penetration is expected only when the antibody recognizes intermediately or highly abundant target in periphery, but will be negligible for antibodies with low abundant peripheral targets which have exquisitely long pharmacokinetic profiles. Despite the efficiency of BBB transcytosis demonstrated with affinity>optimized TfR antibodies, due to above limitation, each therapeutic application will require an extensive tailoring of molecular formats to achieve acceptable risk>benefit profiles.
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The 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Table 4 ).
B) Serum and CSF levels of variants at the end of experiment in A (at 240 min) are measured by multiplexed SRM. Significant increase in CSF levels was measured for OX26 76 >Gal and OX26 108 >Gal conjugates compared to control antibody NiP228>Gal conjugate. The levels of OX26 6 dosed at 30 nmol/kg were also included (see corresponding potency data in Table 4 ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
